KRAS and neoplasm: However, our analysis suggests that the molecular characterization of tumors may help on this point: patients with a TP53 mutated or a KRAS+TP53 co-mutated tumor seem to have a poor prognosis and maybe they could represent the group of patients which can benefit effectively from chemo-immunotherapy in the neoadjuvant or adjuvant setting in very early stage (stage I).